• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

雄激素剥夺治疗前列腺癌中 HSD3B1 基因型对疗效影响的独立验证。

Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer.

机构信息

University of Utah Huntsman Cancer Institute, Salt Lake City2Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City.

Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City.

出版信息

JAMA Oncol. 2017 Jun 1;3(6):856-857. doi: 10.1001/jamaoncol.2017.0147.

DOI:10.1001/jamaoncol.2017.0147
PMID:28208175
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5824318/
Abstract

Using data from a prostate cancer registry, this study correlated genotype with response to androgen-deprivation therapy in patients with prostate cancer.

摘要

本研究使用前列腺癌登记处的数据，将基因型与前列腺癌患者对去势治疗的反应相关联。

相似文献

1
Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer.雄激素剥夺治疗前列腺癌中 HSD3B1 基因型对疗效影响的独立验证。
JAMA Oncol. 2017 Jun 1;3(6):856-857. doi: 10.1001/jamaoncol.2017.0147.
2
HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.HSD3B1与前列腺癌雄激素剥夺治疗耐药性：一项回顾性多队列研究
Lancet Oncol. 2016 Oct;17(10):1435-1444. doi: 10.1016/S1470-2045(16)30227-3. Epub 2016 Aug 27.
3
Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer.HSD3B1 基因型与局部前列腺癌放疗后生化复发行雄激素剥夺治疗反应的相关性研究。
JAMA Oncol. 2018 Apr 1;4(4):558-562. doi: 10.1001/jamaoncol.2017.3164.
4
HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.HSD3B1 与非甾体 CYP17A1 抑制剂在去势抵抗性前列腺癌中的反应。
JAMA Oncol. 2018 Apr 1;4(4):554-557. doi: 10.1001/jamaoncol.2017.3159.
5
Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone.HSD3B1 错义多态性与接受雄激素剥夺治疗或阿比特龙治疗的前列腺癌男性患者结局的相关性。
JAMA Netw Open. 2019 Feb 1;2(2):e190115. doi: 10.1001/jamanetworkopen.2019.0115.
6
Germline HSD3B1 Genetics and Prostate Cancer Outcomes.胚系 HSD3B1 遗传学与前列腺癌结局。
Urology. 2020 Nov;145:13-21. doi: 10.1016/j.urology.2020.08.028. Epub 2020 Aug 28.
7
HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.HSD3B1 状态作为雄激素剥夺抵抗的生物标志物及其对前列腺癌的影响。
Nat Rev Urol. 2018 Mar;15(3):191-196. doi: 10.1038/nrurol.2017.201. Epub 2017 Dec 12.
8
HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer.HSD3B1 变体与前列腺癌去势治疗的结局。
Cancer Chemother Pharmacol. 2021 Jan;87(1):103-112. doi: 10.1007/s00280-020-04192-z. Epub 2020 Nov 3.
9
Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer.HSD3B1（1245A>C）种系变异与醋酸阿比特龙联合泼尼松治疗新发转移性去势抵抗性前列腺癌男性患者的反应。
Clin Genitourin Cancer. 2018 Aug;16(4):288-292. doi: 10.1016/j.clgc.2018.03.006. Epub 2018 Mar 27.
10
HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES.HSD3B1 基因型与雄激素剥夺治疗和恩杂鲁胺治疗转移性激素敏感性前列腺癌的结局：ARCHES 研究。
Cell Rep Med. 2024 Aug 20;5(8):101644. doi: 10.1016/j.xcrm.2024.101644.

引用本文的文献

1
Prostate cancer germline variants with therapeutic implications.具有治疗意义的前列腺癌种系变异
Trends Mol Med. 2025 Jul 30. doi: 10.1016/j.molmed.2025.07.004.
2
Fine structural design of 3βHSD1 inhibitors for prostate cancer therapy.用于前列腺癌治疗的3βHSD1抑制剂的精细结构设计。
Proc Natl Acad Sci U S A. 2025 Jul;122(26):e2422267122. doi: 10.1073/pnas.2422267122. Epub 2025 Jun 25.
3
HSD3B1, prostate cancer mortality and modifiable outcomes.3β-羟基类固醇脱氢酶1型、前列腺癌死亡率与可改变的结局
Nat Rev Urol. 2025 May;22(5):313-320. doi: 10.1038/s41585-024-00953-0. Epub 2024 Nov 14.
4
Evaluation of 3β-hydroxysteroid dehydrogenase activity using progesterone and androgen receptors-mediated transactivation.利用孕激素和雄激素受体介导的转录激活作用评价 3β-羟甾脱氢酶活性。
Front Endocrinol (Lausanne). 2024 Oct 2;15:1480722. doi: 10.3389/fendo.2024.1480722. eCollection 2024.
5
Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance.具有转移性激素敏感型前列腺癌和肾上腺允许型 HSD3B1 遗传的男性的生存情况。
J Clin Invest. 2024 Sep 17;134(18):e183583. doi: 10.1172/JCI183583.
6
Body composition as a determinant of the therapeutic index with androgen signaling inhibition.身体成分作为雄激素信号抑制治疗指数的一个决定因素。
Prostate Cancer Prostatic Dis. 2024 Jul 17. doi: 10.1038/s41391-024-00870-8.
7
Adrenal-Permissive Germline HSD3B1 Allele and Prostate Cancer Outcomes.肾上腺允许型生殖系 HSD3B1 等位基因与前列腺癌结局。
JAMA Netw Open. 2024 Mar 4;7(3):e242976. doi: 10.1001/jamanetworkopen.2024.2976.
8
Targeting sex steroid biosynthesis for breast and prostate cancer therapy.针对性类固醇生物合成进行乳腺癌和前列腺癌治疗。
Nat Rev Cancer. 2023 Sep 8. doi: 10.1038/s41568-023-00609-y.
9
Genomic and Phenotypic Biomarkers for Precision Medicine Guidance in Advanced Prostate Cancer.用于晚期前列腺癌精准医学指导的基因组和表型生物标志物
Curr Treat Options Oncol. 2023 Oct;24(10):1451-1471. doi: 10.1007/s11864-023-01121-z. Epub 2023 Aug 10.
10
Regulatory genes in the androgen production, uptake and conversion (APUC) pathway in advanced prostate cancer.晚期前列腺癌雄激素产生、摄取和转化（APUC）途径中的调控基因。
Endocr Oncol. 2022 Jun 7;2(1):R51-R64. doi: 10.1530/EO-22-0058. eCollection 2022 Jan.

本文引用的文献

1
HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.HSD3B1与前列腺癌雄激素剥夺治疗耐药性：一项回顾性多队列研究
Lancet Oncol. 2016 Oct;17(10):1435-1444. doi: 10.1016/S1470-2045(16)30227-3. Epub 2016 Aug 27.
2
A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer.雄激素合成中的功能获得性突变与去势抵抗性前列腺癌。
Cell. 2013 Aug 29;154(5):1074-1084. doi: 10.1016/j.cell.2013.07.029.
3
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.进展性前列腺癌和睾酮去势水平患者的临床试验设计与终点：前列腺癌临床试验工作组的建议
J Clin Oncol. 2008 Mar 1;26(7):1148-59. doi: 10.1200/JCO.2007.12.4487.
4
Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family.3β-羟基类固醇脱氢酶/δ5-δ4异构酶基因家族的分子生物学
Endocr Rev. 2005 Jun;26(4):525-82. doi: 10.1210/er.2002-0050. Epub 2005 Jan 4.